Literature DB >> 4034615

Scopolamine degrades spatial working memory but spares spatial reference memory: dissimilarity of anticholinergic effect and restriction of distal visual cues.

W W Beatty, R A Bierley.   

Abstract

The influence of the centrally active anticholinergic, scopolamine hydrobromide, on working and reference memory was studied in rats tested in a 12-arm radial maze. Both 0.25 and 0.5 mg/kg doses of the drug increased the number of working memory (WM) errors but had no effect on reference memory (RM) errors. A lower dose (0.125 mg/kg) was ineffective, as was the peripherally active anticholinergic, scopolamine methylbromide (0.5 mg/kg). Some of the behavioral effects of anticholinergics on spatial memory are mimicked by blindness or eliminating distal visual cues. If distal visual cues were more important for maintaining accurate WM than for RM, the selective effect of scopolamine on WM could be easily explained. But surrounding the maze with a curtain to eliminate extramaze cues increased RM errors without significantly increasing WM errors. Thus, the selective effect of anticholinergies on spatial memory in the radial maze is qualitatively different from the effect of restricting distal visual cues and must arise from some other action of the drug.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4034615     DOI: 10.1016/0091-3057(85)90120-0

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  12 in total

1.  Effects of scopolamine on repeated acquisition of radial-arm maze performance by rats.

Authors:  D B Peele; S P Baron
Journal:  J Exp Anal Behav       Date:  1988-03       Impact factor: 2.468

Review 2.  Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part II.

Authors:  M Sarter; J Hagan; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Discovery of antidepressant activity by forced swimming test may depend on pre-exposure of rats to a stressful situation.

Authors:  F Borsini; A Lecci; A Sessarego; R Frassine; A Meli
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Behavioral microanalysis of spatial delayed alternation performance: rehearsal through overt behavior, and effects of scopolamine and chlordiazepoxide.

Authors:  P Dudchenko; M Sarter
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 5.  Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: an overview of preclinical and clinical findings.

Authors:  Susanne Graef; Peter Schönknecht; Osama Sabri; Ulrich Hegerl
Journal:  Psychopharmacology (Berl)       Date:  2011-01-08       Impact factor: 4.530

6.  Attenuation of scopolamine-induced spatial memory deficits in the rat by cholinomimetic and non-cholinomimetic drugs using a novel task in the 12-arm radial maze.

Authors:  R P Dennes; J C Barnes
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Central cholinergic involvement in sequential behavior: impairments of performance by atropine in a serial multiple choice task for rats.

Authors:  Stephen B Fountain; James D Rowan; Michael O Wollan
Journal:  Neurobiol Learn Mem       Date:  2013-07-18       Impact factor: 2.877

Review 8.  Psychobiological evidence for the distinction between episodic and semantic memory.

Authors:  M D Horner
Journal:  Neuropsychol Rev       Date:  1990-12       Impact factor: 7.444

9.  Intraseptal injection of the 5-HT1A/5-HT7 agonist 8-OH-DPAT and working memory in rats.

Authors:  Hélène Jeltsch; Fabrice Bertrand; Rodrigue Galani; Christine Lazarus; Sarah Schimchowitsch; Jean-Christophe Cassel
Journal:  Psychopharmacology (Berl)       Date:  2004-03-11       Impact factor: 4.530

10.  Effects of physostigmine and scopolamine on rats' performances in object-recognition and radial-maze tests.

Authors:  A Ennaceur; K Meliani
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.